Differences in plasma microRNA content impair microRNA-based signature for breast cancer diagnosis in cohorts recruited from heterogeneous environmental sites.
[en] Circulating microRNAs are non-invasive biomarkers that can be used for breast cancer diagnosis. However, differences in cancer tissue microRNA expression are observed in populations with different genetic/environmental backgrounds. This work aims at checking if a previously identified diagnostic circulating microRNA signature is efficient in other genetic and environmental contexts, and if a universal circulating signature might be possible. Two populations are used: women recruited in Belgium and Rwanda. Breast cancer patients and healthy controls were recruited in both populations (Belgium: 143 primary breast cancers and 136 healthy controls; Rwanda: 82 primary breast cancers and 73 healthy controls; Ntot = 434), and cohorts with matched age and cancer subtypes were compared. Plasmatic microRNA profiling was performed by RT-qPCR. Random Forest was used to (1) evaluate the performances of the previously described breast cancer diagnostic tool identified in Belgian-recruited cohorts on Rwandan-recruited cohorts and vice versa; (2) define new diagnostic signatures common to both recruitment sites; (3) define new diagnostic signatures efficient in the Rwandan population. None of the circulating microRNA signatures identified is accurate enough to be used as a diagnostic test in both populations. However, accurate circulating microRNA signatures can be found for each specific population, when taken separately.
Disciplines :
Oncology
Author, co-author :
Uyisenga, Jeanne P. ✱; Université de Liège - ULiège > GIGA Research Institute > Génétique Humaine > PhD Thesis
Debit, Ahmed ✱; Université de Liège - ULiège > GIGA Research Institute > Human Genetics > PhD Thesis
Poulet, Christophe ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Département des sciences biomédicales et précliniques
Frères, Pierre ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Oncologie Médicale
Poncin, Aurélie ; Centre Hospitalier Universitaire de Liège - CHU > Médecine interne > Oncologie Médicale
Thiry, Jérôme ; Université de Liège - ULiège > GIGA Research Institute > Génétique Humaine
Mutesa, Leon; University of Rwanda > College of Medicine and Health Sciences > Center for Human Genetics
Jerusalem, Guy ; Université de Liège - ULiège > Département des sciences cliniques > Oncologie
Bours, Vincent ✱; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Génétique humaine
JOSSE, Claire ✱; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service d'oncologie médicale
✱ These authors have contributed equally to this work.
Language :
English
Title :
Differences in plasma microRNA content impair microRNA-based signature for breast cancer diagnosis in cohorts recruited from heterogeneous environmental sites.
Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68, 394–424 (2018). DOI: 10.3322/caac.21492
Belgian Cancer Registry. https://kankerregister.org/Home_en.
Brinton, L. A. et al. Breast cancer in Sub-Saharan Africa: Opportunities for prevention. Breast Cancer Res. Treat. 144, 467–478 (2014). DOI: 10.1007/s10549-014-2868-z
Jedy-Agba, E., McCormack, V., Adebamowo, C. & Dos-Santos-Silva, I. Stage at diagnosis of breast cancer in sub-Saharan Africa: A systematic review and meta-analysis. Lancet. Glob. Heal. 4, e923–e935 (2016). DOI: 10.1016/S2214-109X(16)30259-5
Uyisenga, J. P. et al. Prevalence of histological characteristics of breast cancer in Rwanda in relation to age and tumor stages. Horm. Cancer 10.1007/s12672-020-00393-3 (2020). DOI: 10.1007/s12672-020-00393-3
Checka, C. M., Chun, J. E., Schnabel, F. R., Lee, J. & Toth, H. The relationship of mammographic density and age: Implications for breast cancer screening. AJR Am. J. Roentgenol. 198, W292–W295 (2012). DOI: 10.2214/AJR.10.6049
Gion, M. et al. CA27.29: A valuable marker for breast cancer management. A confirmatory multicentric study on 603 cases. Eur. J. Cancer (Oxf. Engl.) 37, 355–363 (2001). DOI: 10.1016/S0959-8049(00)00396-8
Serpico, D., Molino, L. & Di Cosimo, S. MicroRNAs in breast cancer development and treatment. Cancer Treat. Rev. 40, 595–604 (2014). DOI: 10.1016/j.ctrv.2013.11.002
Wang, W. & Luo, Y. MicroRNAs in breast cancer: Oncogene and tumor suppressors with clinical potential. J. Zhejiang Univ. Sci. B 16, 18–31 (2015). DOI: 10.1631/jzus.B1400184
Hamam, R. et al. microRNA expression profiling on individual breast cancer patients identifies novel panel of circulating microRNA for early detection. Sci. Rep. 6, 25997 (2016). DOI: 10.1038/srep25997
Hemmatzadeh, M., Mohammadi, H., Jadidi-Niaragh, F., Asghari, F. & Yousefi, M. The role of oncomirs in the pathogenesis and treatment of breast cancer. Biomed. Pharmacother. 78, 129–139 (2016). DOI: 10.1016/j.biopha.2016.01.026
Loh, H. Y. et al. The regulatory role of microRNAs in breast cancer. Int. J. Mol. Sci. 20, 1–27 (2019). DOI: 10.3390/ijms20194940
Gu, X., Xue, J.-Q., Han, S.-J., Qian, S.-Y. & Zhang, W.-H. Circulating microRNA-451 as a predictor of resistance to neoadjuvant chemotherapy in breast cancer. Cancer Biomark. 16, 395–403 (2016). DOI: 10.3233/CBM-160578
Odenthal, M. et al. Serum microRNA profiles as prognostic/predictive markers in the multimodality therapy of locally advanced adenocarcinomas of the gastroesophageal junction. Int. J. Cancer 137, 230–237 (2015). DOI: 10.1002/ijc.29363
Li, Q. et al. Circulating miR-19a and miR-205 in Serum May Predict the sensitivity of luminal A subtype of breast cancer patients to neoadjuvant chemotherapy with epirubicin plus paclitaxel. PLoS ONE 9, e104870 (2014). DOI: 10.1371/journal.pone.0104870
Müller, V. et al. Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy: A translational research project within the Geparquinto trial. Breast Cancer Res. Treat. 147, 61–68 (2014). DOI: 10.1007/s10549-014-3079-3
Dluzen, D. F. et al. Racial differences in microRNA and gene expression in hypertensive women. Sci. Rep. 6, 35815 (2016). DOI: 10.1038/srep35815
Wang, X. et al. Determination of 14 circulating microRNAs in Swedes and Iraqis with and without diabetes mellitus type 2. PLoS ONE 9, 1–8 (2014).
Wang, T. et al. A micro-RNA signature associated with race, tumor size, and target gene activity in human uterine leiomyomas. Genes. Chromosomes Cancer 46, 336–347 (2007). DOI: 10.1002/gcc.20415
Huang, R. S. et al. Population differences in microRNA expression and biological implications. RNA Biol. 8, 692–701 (2011). DOI: 10.4161/rna.8.4.16029
Nassar, F. J. et al. MicroRNA expression in ethnic specific early stage breast cancer: An integration and comparative analysis. Sci. Rep. 7, 1–12 (2017). DOI: 10.1038/s41598-016-0028-x
Pollard, J. et al. Differential expression of MicroRNAs in breast cancers from four different ethnicities. Pathobiology 85, 220–226 (2018). DOI: 10.1159/000488456
Gong, Z. et al. Differences in microRNA expression in breast cancer between women of African and European ancestry. Carcinogenesis 40, 61–69 (2019). DOI: 10.1093/carcin/bgy134
Lara, O. D. et al. Pan-cancer clinical and molecular analysis of racial disparities. Cancer 126, 800–807 (2020). DOI: 10.1002/cncr.32598
Frères, P. et al. Circulating microRNA-based screening tool for breast cancer. Oncotarget 7, 5416–5428 (2016). DOI: 10.18632/oncotarget.6786
Breiman, L. Random forests. Mach. Learn. 45, 5–32 (2001). DOI: 10.1023/A:1010933404324
Youden, W. J. Index for rating diagnostic tests. Cancer 3, 32–35 (1950). DOI: 10.1002/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3
Coleman, C. Early detection and screening for breast cancer. Semin. Oncol. Nurs. 33, 141–155 (2017). DOI: 10.1016/j.soncn.2017.02.009
Bleyer, A. & Welch, H. G. Effect of three decades of screening mammography on breast-cancer incidence. N. Engl. J. Med. 367, 1998–2005 (2012). DOI: 10.1056/NEJMoa1206809
Aggarwal, T. et al. MicroRNAs as biomarker for breast cancer. Endocr. Metab. Immune Disord. Drug Targets 20, 1597–1610 (2020). DOI: 10.2174/1871530320666200428113051
Yang, Z. & Liu, Z. The emerging role of MicroRNAs in breast cancer. J. Oncol. 2020, 9160905 (2020).
Yu, F. et al. let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 131, 1109–1123 (2007). DOI: 10.1016/j.cell.2007.10.054
Tavazoie, S. F. et al. Endogenous human microRNAs that suppress breast cancer metastasis. Nature 451, 147–152 (2008). DOI: 10.1038/nature06487
Huang, S. et al. miR-150 promotes human breast cancer growth and malignant behavior by targeting the pro-apoptotic purinergic P2X7 receptor. PLoS ONE 8, e80707 (2013). DOI: 10.1371/journal.pone.0080707
Li, H. et al. A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients. Nat. Commun. 9, 1614 (2018). DOI: 10.1038/s41467-018-03537-w
Hashimoto, K. et al. Cancer-secreted hsa-miR-940 induces an osteoblastic phenotype in the bone metastatic microenvironment via targeting ARHGAP1 and FAM134A. Proc. Natl. Acad. Sci. 115, 2204–2209 (2018). DOI: 10.1073/pnas.1717363115
Pisano, E. D. et al. Diagnostic performance of digital versus film mammography for breast-cancer screening. N. Engl. J. Med. 353, 1773–1783 (2005). DOI: 10.1056/NEJMoa052911
Lehman, C. D. et al. National performance benchmarks for modern screening digital mammography: Update from the breast cancer surveillance consortium. Radiology 283, 49–58 (2017). DOI: 10.1148/radiol.2016161174
Poplack, S. P., Tosteson, A. N., Grove, M. R., Wells, W. A. & Carney, P. A. Mammography in 53,803 women from the New Hampshire mammography network. Radiology 217, 832–840 (2000). DOI: 10.1148/radiology.217.3.r00dc33832
Zhao, H. et al. A pilot study of circulating miRNAs as potential biomarkers of early stage breast cancer. PLoS ONE 5, e13735 (2010). DOI: 10.1371/journal.pone.0013735
Rawlings-Goss, R. A., Campbell, M. C. & Tishkoff, S. A. Global population-specific variation in miRNA associated with cancer risk and clinical biomarkers. BMC Med. Genomics 7, 53 (2014). DOI: 10.1186/1755-8794-7-53
Souza, K. C. B. et al. Identification of cell-free circulating microRNAs for the detection of early breast cancer and molecular subtyping. J. Oncol. 2019, 1–11 (2019). DOI: 10.1155/2019/8393769
Saleh, A. A., Soliman, S. E., Habib, M. S. E., Gohar, S. F. & Abo-Zeid, G. S. Potential value of circulatory microRNA122 gene expression as a prognostic and metastatic prediction marker for breast cancer. Mol. Biol. Rep. 46, 2809–2818 (2019). DOI: 10.1007/s11033-019-04727-5
Yerukala Sathipati, S. & Ho, S.-Y. Identifying a miRNA signature for predicting the stage of breast cancer. Sci. Rep. 8, 16138 (2018). DOI: 10.1038/s41598-018-34604-3
Stückrath, I. et al. Aberrant plasma levels of circulating miR-16, miR-107, miR-130a and miR-146a are associated with lymph node metastasis and receptor status of breast cancer patients. Oncotarget 6, 13387–13401 (2015). DOI: 10.18632/oncotarget.3874
Determan, C. E. Jr. Optimal algorithm for metabolomics classification and feature selection varies by dataset. Int. J. Biol. 7, 100–115 (2014).
